Company intelligence / Profile preview

Shijiazhuang Sagacity New Drug Development Co., Ltd.

Shijiazhuang, Hebei, China

Ownership: Private
Development stage: Other

Overview

SC0191, a small molecule inhibitor of Wee1 kinase, has demonstrated excellent antitumor efficacy in TP53 mutant solid cancer preclinical studies, showing better results than AZD1775 in NCI-H446 and BxPC-3 CDX mouse models[4].

Therapeutic areas: OtherOncologyImmunology
Modalities: Small molecules
Industry: Biotech

Beyond the preview

Go deeper on Shijiazhuang Sagacity New Drug Development Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shijiazhuang Sagacity New Drug Development Co., Ltd..